Prognostic value of promoter hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in prostate cancer

Chinese Journal of Cancer Research

Volumn 23, Issue 4, 2011, Pages 306-311

  Ameri, A ^a   Alidoosti, A ^a   Hosseini, Y ^b   Parvin, M ^c   Emranpour, M H ^a   Taslimi, F ^a   Salehi, E ^d   Fadavi, P ^d  

^a SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

CDKN2 (p16 MTS1); CpG island; DNA methylation; Methylation Specific PCR; Prostate cancer; Retinoic acid receptor beta (RARB)

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID RECEPTOR BETA;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; GLEASON SCORE; HUMAN; HUMAN TISSUE; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY;

EID: 84856743589     PISSN: 10009604     EISSN: 19930631     Source Type: Journal    
DOI: 10.1007/s11670-011-0306-x     Document Type: Article

References (37)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59:225-49.
2. Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108. (Pubitemid 40372904)
3. Perry AS, Foley R, Woodson K, et al. The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr Relat Cancer 2006; 13:357-77. (Pubitemid 43886663)
4. Hughes C, Murphy A, Martin C, et al. Molecular pathology of prostate cancer. J Clin Pathol 2005; 58:673-84. (Pubitemid 40956818)
5. Hoque MO. DNA methylation changes in prostate cancer: current developments and future clinical implementation. Expert Rev Mol Diagn 2009; 9:243-57.
6. Cho NY, Kim JH, Moon KC, et al. Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch 2009; 454:17-23.
7. Richiardi L, Fiano V, Vizzini L, et al. Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. J Clin Oncol 2009; 27:3161-8.
8. Blute ML, Bergstralh EJ, Iocca A, et al. Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol 2001; 165: 119-25.
9. Roberts WW, Bergstralh EJ, Blute ML, et al. Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. Urology 2001; 57:1033-7. (Pubitemid 32455561)
10. Partin AW, Kattan MW, Subong EN, et al. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997; 277:1445-51. (Pubitemid 27208886)
11. Scher WI. Cancer of the Prostate. In DeVita VT Jr, Hellman S, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, 7th ed. Philadelphia, Pa: Lippincott Williams & Wilkins: 2005; 1192-50.
12. Murphy TM, Perry AS, Lawler M. The emergence of DNA methylation as a key modulator of aberrant cell death in prostate cancer. Endocr Relat Cancer 2008; 15:11-25. (Pubitemid 351449724)
13. Jerónimo C, Henrique R, Sidransky D. Uses of DNA methylation in cancer diagnosis and risk assessment. In: Esteller M, editor. DNA methylation. Approaches, methods and applications. CRC Press: Boca Raton 2004; 11-26.
14. Costa VL, Henrique R, Jerónimo C. Epigenetic markers for molecular detection of prostate cancer. Dis Markers 2007; 23:31-41. (Pubitemid 46333639)
15. Zhou SG, Sun YH, Gao JP. DNA methylation and prostate cancer. Zhonghua Nan Ke Xue 2007; 13:1108-12.
16. Kang GH, Lee S, Lee HJ, et al. Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. J Pathol 2004; 202:233-40. (Pubitemid 38208661)
17. Nakayama M, Gonzalgo ML, Yegnasubramanian S, et al. GSTP1 CpG island hypermethylation as a molecular biomarker for prostate cancer. J Cell Biochem 2004; 91:540-52.
18. Bastian PJ, Palapattu GS, Lin X, et al. Preoperative serum DNA GSTP1 CpG island hypermethylation and the risk of early prostate-specific antigen recurrence following radical prostatectomy. Clin Cancer Res 2005; 11: 4037-43. (Pubitemid 40791567)
19. Enokida H, Shiina H, Urakami S, et al. Ethnic group-related differences in CpG hypermethylation of the GSTP1 gene promoter among African-American, Caucasian and Asian patients with prostate cancer. Int J Cancer 2005; 116:174-81. (Pubitemid 40967252)
20. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res 2002; 8:514-9. (Pubitemid 34193971)
21. Bastian PJ, Ellinger J, Wellmann A, et al. Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. Clin Cancer Res 2005; 11:4097-106. (Pubitemid 40791574)
22. Woodson K, Hayes R, Wideroff L, et al. Hypermethylation of GSTP1, CD44, and E-cadherin genes in prostate cancer among US Blacks and Whites. Prostate 2003; 55:199-205. (Pubitemid 36532399)
23. Zhang J, Liu L, Pfeifer GP. Methylation of the retinoid response gene TIG1 in prostate cancer correlates with methylation of the retinoic acid receptor beta gene. Oncogene 2004; 23: 2241-9. (Pubitemid 38482540)
24. Yao Q, He XS, Zhang JM, et al. Promotor hypermethylation of E-cadherin, p16 and estrogen receptor in prostate carcinoma. Zhonghua Nan Ke Xue 2006; 12:28-31.
25. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/p16/ MTS1 gene is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995; 55:4525-30.
26. Jarrard DF, Bova GS, Ewing CM, et al. Deletional, mutational, and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 1997; 19:90-6. (Pubitemid 27231483)
27. Nakayama T, Watanabe M, Yamanaka M, et al. The role of epigenetic modifications in retinoic acid receptor beta2 gene expression in human prostate cancers. Lab Invest 2001; 81:1049-57. (Pubitemid 32645980)
28. Bastian PJ, Ellinger J, Heukamp LC, et al. Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol 2007; 51:665-74. (Pubitemid 46097267)
29. Herman JG, Graff JR, Myöhänen S, et al. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 1996; 93:9821-6. (Pubitemid 26296693)
30. Arafa M, Kridelka F, Mathias V, et al. High frequency of RASSF1Aand RARb2gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma. Histopathology 2008; 53: 525-32.
31. Rosenbaum E, Hoque MO, Cohen Y, et al. Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. Clin Cancer Res 2005; 11:8321-5. (Pubitemid 41746943)
32. Salem C, Liang G, Tsai YC, et al. Progressive increases in de novo methylation of CpG islands in bladder cancer. Cancer Res 2000; 60:2473-6. (Pubitemid 30262439)
33. Maruyama R, Toyooka S, Toyooka KO, et al. Aberrant promoter methylation profile of bladder cancer and its relationship to clinicopathological features. Cancer Res 2001; 61:8659-63. (Pubitemid 34013873)
34. Chan MW, Chan LW, Tang NL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002; 8:464-70. (Pubitemid 34193966)
35. Tada Y, Wada M, Taguchi K, et al. The association of death associated protein kinase hypermethylation with early recurrence in superficial bladder cancer. Cancer Res 2002; 62:4048-53. (Pubitemid 34791073)
36. Catto JW, Azzouzi AR, Rehman I, et al. Promoter hypermethylation is associated with tumor location, stage, and subsequent progression in transitional cell carcinoma. J Clin Oncol 2005; 23:2903-10. (Pubitemid 46224108)
37. Henrique R, Ribeiro FR, Fonseca D, et al. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. Clin Cancer Res 2007; 13:6122-9. (Pubitemid 350075071)